Wednesday, 16 October 2024
  
Login

Australia's most trusted
source of pharma news

Wednesday, 16 October 2024
News

The drug class to eclipse all others

 Posted 14 October 2024 AM

Expanding beyond weight loss will see incretins become the highest earning class of pharmaceutical drugs ever, according to a recent report from Evaluate.

According to the report, Obesity: The next questions, many analysts expect the incretin class of drugs to become biopharma's first drug class to hit annual sales of US$100 billion, with some predicting the market could end up closer to US$200 billion.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (17)

Clinical & Medical, R&D (17)

Regulatory, Pharmacovigilance & QA (7)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.